New combo therapy shows promise for Hard-to-Treat breast cancers

NCT ID NCT06612203

First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 18 times

Summary

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors. The study includes two types of breast cancer: triple-negative and HR+/HER2-.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barts Health NHS Trust

    London, United Kingdom

  • Beatson West of Scotland Cancer Center

    Glasgow, United Kingdom

  • Hospital Arnau de Vilanova de Valencia

    Valencia, Spain

  • Hospital Beata María Ana

    Madrid, Spain

  • Hospital Universitari Dexeus

    Barcelona, Spain

  • Hospital Universitario Clínico San Cecilio de Granada

    Granada, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

Conditions

Explore the condition pages connected to this study.